[go: up one dir, main page]

EA200100671A1 - ПРОИЗВОДНЫЕ 2,3,4,4a-ТЕТРАГИДРО-1H-ПИРАЗИНО [1,2a]ХИНОКСАЛИН-5(6H)-ОНА, ЯВЛЯЮЩИЕСЯ АГОНИСТАМИ 5HT2C - Google Patents

ПРОИЗВОДНЫЕ 2,3,4,4a-ТЕТРАГИДРО-1H-ПИРАЗИНО [1,2a]ХИНОКСАЛИН-5(6H)-ОНА, ЯВЛЯЮЩИЕСЯ АГОНИСТАМИ 5HT2C

Info

Publication number
EA200100671A1
EA200100671A1 EA200100671A EA200100671A EA200100671A1 EA 200100671 A1 EA200100671 A1 EA 200100671A1 EA 200100671 A EA200100671 A EA 200100671A EA 200100671 A EA200100671 A EA 200100671A EA 200100671 A1 EA200100671 A1 EA 200100671A1
Authority
EA
Eurasian Patent Office
Prior art keywords
carbon atoms
alkyl
represents hydrogen
disorders
aroyl
Prior art date
Application number
EA200100671A
Other languages
English (en)
Inventor
Аннмари Луиз Сабб
Грегори Скотт Велмейкер
Джеймс Альберт Нельсон
Original Assignee
Американ Хоум Продактс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Американ Хоум Продактс Корпорейшн filed Critical Американ Хоум Продактс Корпорейшн
Publication of EA200100671A1 publication Critical patent/EA200100671A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение предлагает соединения формулы (I)в которой R представляет водород или алкил с 1-6 атомами углерода; R' представляет водород, алкил с 1-6 атомами углерода, ацил с 2-7 атомами углерода или ароил; R, R, Rи R, каждый независимо, представляет водород, алкил с 1-6 атомами углерода, алкокси с 1-6 атомами углерода, галоген, трифторалкил, -CN, алкилсульфонамид с 1-6 атомами углерода, алкиламид с 1-6 атомами углерода, амино, алкиламино с 1-6 атомами углерода, диалкиламино с 1-6 атомами углерода в алкильном фрагменте, трифторалкокси с 1-6 атомами углерода, ацил с 2-7 атомами углерода или ароил; X представляет CRRили карбонильную группу; Rи R, каждый независимо, представляет водород или алкил с 1-6 атомами углерода; или их фармацевтически приемлемые соли, при условии, что, по меньшей мере, один из R, R, Rи Rне является водородом, и их энантиомеры, которые являются агонистами 5HT-рецептора, полезными для лечения расстройств, связанных с центральной нервной системой, таких как обсессивно-компульсивные нарушения; депрессия; тревога; состояние паники; шизофрения; мигрень; расстройства сна; расстройства аппетита; ожирение; диабет типа II и эпилепсия.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100671A 1998-12-17 1999-12-16 ПРОИЗВОДНЫЕ 2,3,4,4a-ТЕТРАГИДРО-1H-ПИРАЗИНО [1,2a]ХИНОКСАЛИН-5(6H)-ОНА, ЯВЛЯЮЩИЕСЯ АГОНИСТАМИ 5HT2C EA200100671A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21347198A 1998-12-17 1998-12-17
PCT/US1999/029894 WO2000035922A1 (en) 1998-12-17 1999-12-16 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists

Publications (1)

Publication Number Publication Date
EA200100671A1 true EA200100671A1 (ru) 2001-12-24

Family

ID=22795247

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100671A EA200100671A1 (ru) 1998-12-17 1999-12-16 ПРОИЗВОДНЫЕ 2,3,4,4a-ТЕТРАГИДРО-1H-ПИРАЗИНО [1,2a]ХИНОКСАЛИН-5(6H)-ОНА, ЯВЛЯЮЩИЕСЯ АГОНИСТАМИ 5HT2C

Country Status (18)

Country Link
EP (1) EP1140940A1 (ru)
JP (1) JP2002532504A (ru)
KR (1) KR20010108025A (ru)
CN (1) CN1240701C (ru)
AR (1) AR022687A1 (ru)
AU (1) AU3123400A (ru)
BR (1) BR9916326A (ru)
CA (1) CA2351385A1 (ru)
CZ (1) CZ20012193A3 (ru)
EA (1) EA200100671A1 (ru)
HU (1) HUP0104773A3 (ru)
IL (1) IL143323A0 (ru)
NO (1) NO20013001L (ru)
NZ (1) NZ512765A (ru)
PL (1) PL348815A1 (ru)
SK (1) SK8192001A3 (ru)
WO (1) WO2000035922A1 (ru)
ZA (1) ZA200104598B (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
AU8395501A (en) 2000-07-31 2002-02-13 Hoffmann La Roche Piperazine derivatives
ES2230382T3 (es) * 2000-11-03 2005-05-01 Wyeth Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c.
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031195A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
US7141563B2 (en) 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
ES2328671T3 (es) 2000-11-20 2009-11-17 Biovitrum Ab (Publ) Compuestos de piperazilpirazinas como antagonistas del receptor de serotonina 5-ht2.
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
CA2431970A1 (en) * 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists
CA2432085C (en) 2000-12-27 2009-02-24 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
JPWO2002074746A1 (ja) * 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
EP1392658A4 (en) 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
WO2002098400A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
PL366636A1 (en) 2001-06-01 2005-02-07 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
EA008148B1 (ru) 2002-06-19 2007-04-27 Биовитрум Аб Новые соединения, их применение и получение
WO2004054572A2 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
ES2364046T3 (es) 2002-12-19 2011-08-23 Bristol-Myers Squibb Company Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina.
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
CN1809545A (zh) * 2003-06-20 2006-07-26 艾尼纳制药公司 N－苯基－哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
AU2005291541B2 (en) * 2004-09-30 2011-03-10 F. Hoffmann-La Roche Ag Benzoxazine and quinoxaline derivatives and uses
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
KR101110199B1 (ko) 2009-05-18 2012-03-14 한국화학연구원 피페라진-퀴놀린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
AU2011212930B2 (en) 2010-02-04 2016-02-11 The Board Of Trustees Of The University Of Illinois Highly selective 5-HT(2C) receptor agonists having antagonist activity at the 5-HT(2B) receptor
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2012099952A2 (en) 2011-01-19 2012-07-26 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
HK1251831A1 (zh) 2015-01-29 2019-04-04 The Board Of Trustees Of The University Of Illinois 作為選擇性5-ht(2c)受體激動劑的環丙基甲胺
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
US4089958A (en) * 1976-12-20 1978-05-16 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2]quinoxalin-5(6)-ones and derivatives thereof
US4203987A (en) * 1979-05-21 1980-05-20 American Home Products Corporation 3-[Pyridinylalkyl and piperidinylalkyl]-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-ones
GB8917333D0 (en) * 1989-07-28 1989-09-13 Merck Sharp & Dohme Therapeutic agents
EP0539209A1 (en) * 1991-10-24 1993-04-28 The Upjohn Company Benzo-isoquinoline derivatives and analogs and their use in therapeutics
AU4547796A (en) * 1995-02-03 1996-08-21 Sankyo Company Limited Hexahydropyrazinoquinoline derivatives

Also Published As

Publication number Publication date
BR9916326A (pt) 2001-10-02
HUP0104773A3 (en) 2004-10-28
IL143323A0 (en) 2002-04-21
NO20013001D0 (no) 2001-06-15
NZ512765A (en) 2003-10-31
CZ20012193A3 (cs) 2001-12-12
PL348815A1 (en) 2002-06-17
AR022687A1 (es) 2002-09-04
ZA200104598B (en) 2002-09-05
AU3123400A (en) 2000-07-03
CN1330652A (zh) 2002-01-09
SK8192001A3 (en) 2001-12-03
JP2002532504A (ja) 2002-10-02
HUP0104773A2 (hu) 2002-04-29
CN1240701C (zh) 2006-02-08
EP1140940A1 (en) 2001-10-10
NO20013001L (no) 2001-06-15
KR20010108025A (ko) 2001-12-07
CA2351385A1 (en) 2000-06-22
WO2000035922A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
EA200100671A1 (ru) ПРОИЗВОДНЫЕ 2,3,4,4a-ТЕТРАГИДРО-1H-ПИРАЗИНО [1,2a]ХИНОКСАЛИН-5(6H)-ОНА, ЯВЛЯЮЩИЕСЯ АГОНИСТАМИ 5HT2C
DE60106641D1 (de) Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
IL154272A (en) Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
FI943247A0 (fi) Piperatsiinijohdannaisia 5-HT-reseptoriantagonisteina
PT98168A (pt) Processo para a preparacao de novos derivados do indole e de composicoes farmaceuticas que os contem
NZ330861A (en) Fused pyrrolecarboxamides and use as a new class of GABA brain receptor ligands
GR3025106T3 (en) Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities
ATE171374T1 (de) Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln
LV11320A (lv) 1-arilcikloalkilsulfida sulfoksida vai sulfona atvasinajumu pielietosana depresijas satraukuma Parkinsona slimibas arstesanai
ES2182509T3 (es) Derivados de n-ariloxietilamina para el tratamiento de la depresion.
UA66888C2 (ru) 3-тетрагидропиридин-4-ил индолы, способ их получения и способ лечения психических расстройств
PT1140919E (pt) Novos derivados de ciclohexano 1,4-dissubstituido para o tratamento da depressao
EP0739903A4 (en) CARBAMOYL METHYL URINE DERIVATIVES
ES2188155T3 (es) N-ariloxietilindolilalquilaminas para el tratamiento de la depresion.
ATE200673T1 (de) 1,9-diazabicyclo(4.3.0)nona-3,8-dienderivate
ES2056025A1 (es) Nuevos derivados de indol.